secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2023-02-15T23:59:59+00:00
Accession:  0001193125-23-039757
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm FY2022 total revenue $157.1M, net loss $165.3M; FY2023 guidance $160-175M
--------------------------------------------------------------------------------

- U.S. XPOVIO net product revenue $120.4M in FY2022, up 22% YoY from $98.4M.
- FY2022 net loss $165.3M ($2.02/share) vs net loss $124.1M ($1.65/share) in 2021.
- Cash, cash equivalents and investments $279.7M at Dec 31, 2022; $165M private placement extends cash runway into late 2025.
- FY2023 guidance: total revenue $160-175M, XPOVIO net product revenue $125-140M, non-GAAP R&D+SG&A $260-280M.
- Initiated Phase 3 selinexor maintenance in TP53 wild-type endometrial cancer; Phase 1 MF and Phase 2 MDS data due 1H 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000119312523039757/0001193125-23-039757-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000119312523039757/d374435d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-039757

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer